Extract from the Register of European Patents

EP About this file: EP3697914

EP3697914 - VECTORS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.04.2024
Database last updated on 28.03.2026
FormerThe patent has been granted
Status updated on  05.05.2023
FormerGrant of patent is intended
Status updated on  27.11.2022
FormerExamination is in progress
Status updated on  19.10.2022
FormerGrant of patent is intended
Status updated on  07.06.2022
FormerExamination is in progress
Status updated on  02.07.2021
FormerRequest for examination was made
Status updated on  24.07.2020
FormerThe international publication has been made
Status updated on  26.04.2019
Formerunknown
Status updated on  27.10.2018
Most recent event   Tooltip01.08.2025Lapse of the patent in a contracting state
New state(s): CY
published on 03.09.2025  [2025/36]
Applicant(s)For all designated states
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Carretera de Can Ruti
Camí de les Escoles, s/n
08916 Badalona / ES
For all designated states
Gentec, S.A.
Plaça d'Europa 9-11, 3B
08908 L'Hospitalet de Llobregat (Barcelona) / ES
[2023/19]
Former [2020/35]For all designated states
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Carretera de Can Ruti
Camí de les Escoles, s/n
08916 Badalona / ES
For all designated states
Gentec, S.A.
C. Tarragona, 161, pta. 18
08014 Barcelona / ES
Inventor(s)01 / MATILLA DUEÑAS, Antoni
Fundació Institut D'Investigació en Ciències de la
Salut Germans Trias I Pujol
Carretera de Can Ruti
Camí de les Escoles s/n
08916 Badalona / ES
02 / SÁNCHEZ DÍAZ, Ivelisse
Fundació Institut D'Investigació en Ciències de la
Salut Germans Trias I Pujol
Carretera de Can Ruti
Camí de les Escoles s/n
08916 Badalona / ES
03 / BALAGUÉ CABASÉS, Eudald
Fundació Institut D'Investigació en Ciències de la
Salut Germans Trias I Pujol
Carretera de Can Ruti
Camí de les Escoles s/n
08916 Badalona / ES
 [2020/35]
Representative(s)Hoffmann Eitle
Hoffmann Eitle S.L.U.
Paseo de la Castellana 140, 3a planta
Edificio LIMA
28046 Madrid / ES
[2020/35]
Application number, filing date18786778.317.10.2018
[2020/35]
WO2018EP78384
Priority number, dateEP2017038269117.10.2017         Original published format: EP 17382691
[2020/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019076973
Date:25.04.2019
Language:EN
[2019/17]
Type: A1 Application with search report 
No.:EP3697914
Date:26.08.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 25.04.2019 takes the place of the publication of the European patent application.
[2020/35]
Type: B1 Patent specification 
No.:EP3697914
Date:07.06.2023
Language:EN
[2023/23]
Type: B9 Corrected patent specification 
No.:EP3697914
Date:04.10.2023
[2023/40]
Search report(s)International search report - published on:EP25.04.2019
ClassificationIPC:C12N15/86
[2020/35]
CPC:
C12N15/86 (EP,US); A61K48/005 (US); A61K48/0058 (US);
A61K48/0066 (US); A61P25/00 (US); A61P25/14 (US);
C12N2750/14143 (EP,US); C12N2830/48 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/35]  
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:VEKTOREN ZUR BEHANDLUNG DER FRIEDREICH-ATAXIE[2020/35]
English:VECTORS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA[2020/35]
French:VECTEURS DESTINÉS AU TRAITEMENT DE L'ATAXIE DE FRIEDREICH[2022/23]
Former [2020/35]VECTEURS POUR LE TRAITEMENT DE L'ATAXIE DE FRIEDREICH
Entry into regional phase13.05.2020National basic fee paid 
13.05.2020Designation fee(s) paid 
13.05.2020Examination fee paid 
Examination procedure16.08.2019Request for preliminary examination filed
International Preliminary Examining Authority: EP
13.05.2020Examination requested  [2020/35]
13.05.2020Date on which the examining division has become responsible
04.12.2020Amendment by applicant (claims and/or description)
06.07.2021Despatch of a communication from the examining division (Time limit: M02)
16.09.2021Reply to a communication from the examining division
08.06.2022Communication of intention to grant the patent
17.10.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.11.2022Communication of intention to grant the patent
24.03.2023Fee for grant paid
24.03.2023Fee for publishing/printing paid
24.03.2023Receipt of the translation of the claim(s)
Divisional application(s)EP22170787.0  / EP4089173
Opposition(s)08.03.2024No opposition filed within time limit [2024/20]
Fees paidRenewal fee
19.10.2020Renewal fee patent year 03
18.10.2021Renewal fee patent year 04
18.10.2022Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY17.10.2018
HR07.06.2023
MC07.06.2023
SM07.06.2023
[2025/36]
Former [2024/28]HR07.06.2023
MC07.06.2023
SM07.06.2023
Former [2024/08]HR07.06.2023
SM07.06.2023
Former [2023/51]HR07.06.2023
Cited inInternational search[YD] WO2016150964  (INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) et al.)
 [Y] WO2016115503  (VOYAGER THERAPEUTICS INC et al.)
 [Y] WO2009034127  (INST NAT SANTE RECH MED et al.)
 [Y]   REZAIE E S ET AL: "Intra-luminal gene therapy in the porcine artery using a recombinant adeno-associated virus 9", GENE., vol. 618, 1 June 2017 (2017-06-01), NL, pages 24 - 27, XP055496994, ISSN: 0378-1119, DOI: 10.1016/j.gene.2017.03.019

DOI:   http://dx.doi.org/10.1016/j.gene.2017.03.019
 [Y]   MATTAR C N ET AL: "Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates", THE FASEB JOURNAL, vol. 29, no. 9, 1 September 2015 (2015-09-01), US, pages 3876 - 3888, XP055496998, ISSN: 0892-6638, DOI: 10.1096/fj.14-269092

DOI:   http://dx.doi.org/10.1096/fj.14-269092
by applicantWO2016150964
   GERARD ET AL., MOL THER METHODS CLIN DEV, vol. 1, 2014, pages 14044
   CHAPDELAINE ET AL., GENE THER, vol. 23, no. 7, 2016, pages 606 - 614
   TREMBLAY ET AL., MOL THER., vol. 23, no. 1, 2015, pages S153
   ALTSCHUL ET AL., J MOL BIOL., vol. 215, no. 3, 1990, pages 403 - 10
   "Remington's Pharmaceutical Sciences", 1980
   POOK ET AL., NEUROGENETICS, vol. 3, no. 4, 2001, pages 185 - 93
   VIRMOUNI ET AL., PLOS ONE, vol. 9, no. 9, 2014, pages e107416
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.